New study monitors Aimovig's safety in pregnant women with migraine
NCT ID NCT06150781
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows pregnant women with migraine who take Aimovig (erenumab-aooe) to see if the drug increases the risk of major birth defects. Researchers will compare their babies to those of women with migraine who did not take Aimovig. The goal is to gather real-world safety data for this medication during pregnancy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
erenumab-aooe (Aimovig)
What this could lead to
If successful, this study could provide important safety information about using Aimovig during pregnancy, helping doctors and patients make informed decisions.
What could go wrong
This is an observational registry, not a controlled trial, so it can only show associations, not cause and effect. Results may take years to gather and analyze.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IQVIA Virtual Site
RECRUITINGDurham, North Carolina, 27703, United States